Blood Res.  2019 Mar;54(1):17-22. 10.5045/br.2019.54.1.17.

Recent progress in laboratory diagnosis of thalassemia and hemoglobinopathy: a study by the Korean Red Blood Cell Disorder Working Party of the Korean Society of Hematology

Affiliations
  • 1Department of Laboratory Medicine, Hallym University College of Medicine, Anyang, Korea.
  • 2Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 3Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 4Department of Laboratory Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
  • 5Department of Laboratory Medicine, Seoul National University Hospital and College of Medicine, Seoul, Korea.
  • 6Department of Laboratory Medicine, Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 7Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea. jyhan@dau.ac.kr

Abstract

Genetic hemoglobin disorders are caused by mutations and/or deletions in the α-globin or β-globin genes. Thalassemia is caused by quantitative defects and hemoglobinopathies by structural defect of hemoglobin. The incidence of thalassemia and hemoglobinopathy is increased in Korea with rapid influx of people from endemic areas. Thus, the awareness of the disease is needed. α-thalassemias are caused by deletions in α-globin gene, while β-thalassemias are associated with decreased synthesis of β-globin due to β-globin gene mutations. Hemoglobinopathies involve structural defects in hemoglobin due to altered amino acid sequence in the α- or β-globin chains. When the patient is suspected with thalassemia/hemoglobinopathy from abnormal complete blood count findings and/or family history, the next step is detecting hemoglobin abnormality using electrophoresis methods including high performance liquid chromatography and mass spectrometry. The development of novel molecular genetic technologies, such as massively parallel sequencing, facilitates a more precise molecular diagnosis of thalassemia/hemoglobinopathy. Moreover, prenatal diagnosis using genetic testing enables the prevention of thalassemia birth and pregnancy complications. We aimed to review the spectrum and classification of thalassemia/hemoglobinopathy diseases and the diagnostic strategies including screening tests, molecular genetic tests, and prenatal diagnosis.

Keyword

Thalassemia; Hemoglobinopathies; Anemia; Diagnosis; Genetic testing

MeSH Terms

Amino Acid Sequence
Anemia
Blood Cell Count
Chromatography, Liquid
Classification
Clinical Laboratory Techniques*
Diagnosis
Electrophoresis
Erythrocytes*
Genetic Testing
Hematology*
Hemoglobinopathies*
High-Throughput Nucleotide Sequencing
Humans
Incidence
Korea
Mass Screening
Mass Spectrometry
Molecular Biology
Parturition
Pregnancy Complications
Prenatal Diagnosis
Thalassemia*

Cited by  3 articles

Epidemiological Study of Hereditary Hemolytic Anemia in the Korean Pediatric Population during 1997–2016: a Nationwide Retrospective Cohort Study
Ye Jee Shim, Hye Lim Jung, Hee Young Shin, Hyoung Jin Kang, Jung Yoon Choi, Jeong Ok Hah, Jae Min Lee, Young Tak Lim, Eu Jeen Yang, Hee Jo Baek, Hyoung Soo Choi, Keon Hee Yoo, Jun Eun Park, Seongkoo Kim, Ji Yoon Kim, Eun Sil Park, Ho Joon Im, Hee Won Chueh, Soon Ki Kim, Jae Hee Lee, Eun Sun Yoo, Hyeon Jin Park, Jun Ah Lee, Meerim Park, Hyun Sik Kang, Ji Kyoung Park, Na Hee Lee, Sang Kyu Park, Young-Ho Lee, Seong Wook Lee, Eun Jin Choi, Seom Gim Kong,
J Korean Med Sci. 2020;35(33):e279.    doi: 10.3346/jkms.2020.35.e279.

Molecular basis and diagnosis of thalassemia
Jee-Soo Lee, Sung Im Cho, Sung Sup Park, Moon-Woo Seong
Blood Res. 2021;56(S1):39-43.    doi: 10.5045/br.2021.2020332.

Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia
Hee Won Chueh, Sang Mee Hwang, Ye Jee Shim, Jae Min Lee, Hee Sue Park, Joon Hee Lee, Youngwon Nam, Namhee Kim, Hye Lim Jung, Hyoung Soo Choi, on behalf of Korean RBC Disorder Working Party
Blood Res. 2022;57(2):86-94.    doi: 10.5045/br.2022.2021224.


Reference

1. Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews: Beta-thalassemia. Seattle, WA: University of Washington;2018. Accesed December 2, 2018. at https://www.ncbi.nlm.nih.gov/books/NBK1116/.
2. Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews: Alpha-thalassemia. Seattle, WA: University of Washington;2016. Accesed December 2, 2018. at https://www.ncbi.nlm.nih.gov/books/NBK1435/.
3. Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews: Sickle cell disease. Seattle, WA: University of Washington;2017. Accesed December 2, 2018. at https://www.ncbi.nlm.nih.gov/books/NBK1377/.
4. Ferrão J, Silva M, Gonçalves L, et al. Widening the spectrum of deletions and molecular mechanisms underlying alpha-thalassemia. Ann Hematol. 2017; 96:1921–1929.
Article
5. Russo R, Andolfo I, Manna F, et al. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol. 2018; 93:672–682.
Article
6. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int. 2011; 108:532–540.
7. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018; 391:155–167.
Article
8. Higgs DR, Weatherall DJ. The alpha thalassaemias. Cell Mol Life Sci. 2009; 66:1154–1162.
Article
9. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010; 5:13.
10. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999; 341:99–109.
11. Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. ScientificWorldJournal. 2008; 8:1295–1324.
Article
12. Viprakasit V, Ekwattanakit S. Clinical classification, screening and diagnosis for thalassemia. Hematol Oncol Clin North Am. 2018; 32:193–211.
Article
13. Chaitraiphop C, Sanchaisuriya K, Inthavong S, et al. Thalassemia screening using different automated blood cell counters: consideration of appropriate cutoff values. Clin Lab. 2016; 62:545–552.
Article
14. Chan LC, Ma SK, Chan AY, et al. Should we screen for globin gene mutations in blood samples with mean corpuscular volume (MCV) greater than 80 fL in areas with a high prevalence of thalassaemia? J Clin Pathol. 2001; 54:317–320.
Article
15. Viprakasit V, Limwongse C, Sukpanichnant S, et al. Problems in determining thalassemia carrier status in a program for prevention and control of severe thalassemia syndromes: a lesson from Thailand. Clin Chem Lab Med. 2013; 51:1605–1614.
Article
16. Clarke GM, Higgins TN. Laboratory investigation of hemoglobinopathies and thalassemias: review and update. Clin Chem. 2000; 46:1284–1290.
Article
17. Recommendations of a system for identifying abnormal hemoglobins. By the International Committee for Standardization in Hematology. Blood. 1978; 52:1065–1067.
18. Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol. 2010; 149:35–49.
Article
19. Yun YM, Ji M, Ko DH, et al. Hb variants in Korea: effect on HbA1c using five routine methods. Clin Chem Lab Med. 2017; 55:1234–1242.
Article
20. Kim SY, Lee SH, Cho SI, et al. Molecular identification of the novel Gγ-β hybrid hemoglobin: Hb Gγ-β Ulsan (Gγ through 13; β from 19). Blood Cells Mol Dis. 2010; 45:276–279.
Article
21. Huisman T, Carver M, Baysal E, Efremov G. A Database of Human Hemoglobin Variants and Thalassemias. State College, PA: The Pennsylvania State University;2013. Accesed December, 8, 2018. at http://globin.cse.psu.edu/cgi-bin/hbvar/query_vars3.
22. Sayani FA, Kwiatkowski JL. Increasing prevalence of thalassemia in America: implications for primary care. Ann Med. 2015; 47:592–604.
Article
23. Anwar WA, Khyatti M, Hemminki K. Consanguinity and genetic diseases in North Africa and immigrants to Europe. Eur J Public Health. 2014; 24:Suppl 1. 57–63.
Article
24. Jahng J, Yoon KH. A family with a hemoglobin E variant including a Thai immigrant woman in Korea. Ann Lab Med. 2017; 37:71–73.
Article
25. Lee HS, Lee DY, Kim HJ, Lee IS. Two cases of alpha-thalassemia in Korean children from multicultural family. Clin Pediatr Hematol Oncol. 2011; 18:136–139.
26. Li DZ, Yang YD. Invasive prenatal diagnosis of fetal thalassemia. Best Pract Res Clin Obstet Gynaecol. 2017; 39:41–52.
Article
27. Seale TW, Rennert OM. Prenatal diagnosis of thalassemias and hemoglobinopathies. Ann Clin Lab Sci. 1980; 10:383–394.
28. Shang X, Xu X. Update in the genetics of thalassemia: what clinicians need to know. Best Pract Res Clin Obstet Gynaecol. 2017; 39:3–15.
Article
29. Sanguansermsri T, Thanaratanakorn P, Steger HF, et al. Prenatal diagnosis of hemoglobin Bart's hydrops fetalis by HPLC analysis of hemoglobin in fetal blood samples. Southeast Asian J Trop Med Public Health. 2001; 32:180–185.
30. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet. 2010; 18:1077–1083.
Article
31. Langlois S, Ford JC, Chitayat D. CCMG Prenatal Diagnosis Committee. SOGC Genetics Committee. Carrier screening for thalassemia and hemoglobinopathies in Canada. J Obstet Gynaecol Can. 2008; 30:950–959.
Article
32. Li Y, Hahn S, Holzgreve W. Recent developments in the detection of fetal single gene differences in maternal plasma and the role of size fractionation. Ann N Y Acad Sci. 2006; 1092:285–292.
Article
33. Norwitz ER, Levy B. Noninvasive prenatal testing: the future is now. Rev Obstet Gynecol. 2013; 6:48–62.
34. Papasavva T, van Ijcken WF, Kockx CE, et al. Next generation sequencing of SNPs for non-invasive prenatal diagnosis: challenges and feasibility as illustrated by an application to β-thalassaemia. Eur J Hum Genet. 2013; 21:1403–1410.
Article
35. Li Y, Di Naro E, Vitucci A, et al. Size fractionation of cell-free DNA in maternal plasma improves the detection of a paternally inherited beta-thalassemia point mutation by MALDI-TOF mass spectrometry. Fetal Diagn Ther. 2009; 25:246–249.
Article
36. Breveglieri G, Travan A, D'Aversa E, et al. Postnatal and non-invasive prenatal detection of β-thalassemia mutations based on Taqman genotyping assays. PLoS One. 2017; 12:e0172756.
Article
37. Zafari M, Kosaryan M, Gill P, et al. Non-invasive prenatal diagnosis of β-thalassemia by detection of the cell-free fetal DNA in maternal circulation: a systematic review and meta-analysis. Ann Hematol. 2016; 95:1341–1350.
Article
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr